Royalty Report: Drugs, Pharmaceuticals, Tobacco – Collection: 28258

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Tobacco
  • Nicotine
  • cardiac
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28258

License Grant
The Company entered into an exclusive license agreement with a University to assist in the development of the Nicotine Receptor Agonist technology.  The Licensee has exclusive worldwide licensing rights to develop, manufacture, use and sell products incorporating nicotine and nicotine agonists for therapeutic angiogenesis.
License Property
Nicotine Receptor Agonist technology promotes new growth of blood vessels (known as angiogenesis or vasculogenesis), and has applications in the treatment of heart disease, stroke, limb circulatory disease, and wound healing.

IPSCIO Record ID: 4702

License Grant
The Company entered into an exclusive license agreement with the University to assist in the development of the Nicotine Receptor Agonist technology.
License Property
Nicotine Receptor Agonist technology promotes new growth of blood vessels (known as angiogenesis or vasculogenesis), and has applications in the treatment of heart disease, stroke, limb circulatory disease, and wound healing.

IPSCIO Record ID: 1479

License Grant
The Company sold its nicotine technology and related assets; Nicotrol/Nicorette Inhaler (the 'Inhaler') for use in the nicotine replacement therapy; nicotine vapor inhaler device for use in the smoking cessation industry.
License Property
The technology is a nicotine vapor inhaler designed to satisfy nicotine cravings and give the reforming smoker the feeling of holding a cigarette.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.